Olverembatinib ASCO 2026 CML-CP Update
Decision brief
Answer first · skim in under a minute
Ascentage Pharma has unveiled updated clinical data for Olverembatinib at ASCO 2026, highlighting its potential as a second-line therapy in CML-CP. This article delves into the implications for investors and pharma teams.
Ascentage Pharma’s olverembatinib update at ASCO 2026 refreshed the second-line CML-CP evidence base while investors watched the real EU/US prize: POLARIS-2, the FDA- and EMA-cleared Phase 3 registrational trial that will decide whether this third-generation BCR-ABL1 inhibitor expands beyond China.
Contents10 sections
Key Takeaways
- ASCO 2026 featured a rapid oral on updated olverembatinib second-line CML-CP efficacy and safety (abstract 6510).
- Olverembatinib is already approved in China for T315I-mutated CML-CP/AP and for CML-CP resistant/intolerant to first- and second-generation TKIs.
- POLARIS-2 (NCT06423911) is the global Phase 3 registrational backbone versus bosutinib after ≥2 prior TKIs.
- EMA/FDA approval remains contingent on POLARIS-2 and related packages—not on the ASCO oral alone.
What did Ascentage disclose at ASCO 2026?
On May 31, 2026, Ascentage said in a GlobeNewswire release that updated second-line CML-CP data for olverembatinib (HQP1351) would be presented in a rapid oral session at ASCO 2026 (abstract 6510; first author Weiming Li, MD).
The company positioned the dataset as support for second-line use in chronic-phase disease, including settings without T315I mutation where resistance or intolerance to earlier TKIs remains common. Exact MMR percentages belong to the oral slides/publication; this analysis sticks to the company-confirmed presentation facts rather than inventing response rates.
How is olverembatinib currently approved and reimbursed?
Ascentage states olverembatinib is the first novel third-generation BCR-ABL1 inhibitor approved in China for CML-CP with T315I mutations, CML-AP with T315I mutations, and CML-CP resistant or intolerant to first- and second-generation TKIs, and that it is covered on China’s National Reimbursement Drug List.
For European commercial teams, that China foothold matters as a manufacturing and pharmacovigilance track record, but it is not an EMA marketing authorization. Cross-border access programs and named-patient use remain separate from centralized approval strategy.
What is the POLARIS-2 registrational design?
POLARIS-2 is registered as NCT06423911 on ClinicalTrials.gov. The global, open-label, randomized Phase 3 study estimates enrollment around 285 patients.
Part A randomizes CP-CML patients previously treated with at least two TKIs to olverembatinib versus bosutinib (2:1), with major molecular response rate at 24 weeks as the primary endpoint. Part B evaluates olverembatinib in T315I-mutant CP-CML with MMR by 24 weeks as the primary endpoint. An ASCO trial-in-progress abstract (TPS6608) further describes crossover from bosutinib to olverembatinib if MMR is not achieved by 24 weeks.
Why does this matter for EMA-facing strategy?
Third-generation BCR-ABL1 competition in Europe already includes established options for resistant disease. Olverembatinib’s differentiation claim rests on activity against T315I and compound mutations plus second-line depth of response in non-T315I populations. POLARIS-2’s bosutinib control arm is therefore commercially meaningful: payers will ask whether MMR at 24 weeks justifies switching pathways after two prior TKIs.
Ascentage also flags related registrational work in newly diagnosed Ph+ ALL (POLARIS-1) and SDH-deficient GIST (POLARIS-3). Portfolio teams should keep CML-CP value separate from those indications when modeling peak sales.
What should BD and medical affairs monitor next?
- Full ASCO 2026 oral data tables once peer-reviewed or posted as enduring materials.
- POLARIS-2 primary completion and topline MMR timing on ClinicalTrials.gov updates.
- EMA scientific advice disclosures or phased review announcements, if any become public.
- Safety themes typical of TKIs—cytopenias, cardiovascular/metabolic events—in second-line cohorts.
What remains unproven?
The ASCO update does not, by itself, prove EU approvability, superiority to every second-line TKI, or overall survival benefit. Unsourced claims of specific MMR or CCyR percentages not present in the primary wire are omitted. Olverembatinib should be described as China-approved and globally investigational for Western labels until regulators act.
Related NovaPharma coverage
- Olverembatinib drug profile
- CHMP Approves New Medicines: Key Decisions and Implications
- MaaT Pharma Q1 2026 Update
Frequently Asked Questions
What olverembatinib data did Ascentage present at ASCO 2026?
Ascentage presented updated efficacy and safety data for olverembatinib (HQP1351) as second-line therapy in chronic-phase CML in a rapid oral presentation (abstract 6510) at ASCO 2026, per its May 31, 2026 GlobeNewswire release.
What is POLARIS-2 and why does it matter for EMA/FDA?
POLARIS-2 (NCT06423911) is Ascentage’s global Phase 3 registrational trial comparing olverembatinib with bosutinib in CP-CML after at least two prior TKIs (Part A) and evaluating T315I-mutant patients (Part B). The company describes the program as FDA- and EMA-cleared.
Is olverembatinib approved in Europe?
Olverembatinib is approved in China for specified CML populations, including T315I-mutated disease and resistance/intolerance to earlier TKIs. European approval depends on registrational data and EMA review; it should not be described as EU-approved based on the ASCO update alone.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Olverembatinib.
Unlock full calendar →Ascentage Pharma pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
